Date: 2016-07-07
Type of information: Interim results
phase:
Announcement: interim results
Company: Valneva (France- Austria)
Product: Zika virus vaccine
Action mechanism:
Disease: Zika virus infection
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On July 7, 2016, Valneva announced that it successfully generated a highly purified inactivated vaccine candidate against the Zika virus. The candidate was developed using the same manufacturing platform as the Company’s Japanese encephalitis vaccine, a vaccine which has already been approved by the American * On February 2, 2016, Valneva announced that it is evaluating the development of a Zika vaccine as the virus is spreading rapidly through the Americas. The World Health Organization (WHO) declared Zika an international health emergency. The Zika virus is related to the Japanese encephalitis virus, also an arthropod-borne flavivirus transmitted through mosquito bites, against which Valneva has already developed a vaccine (Ixiaro®/Jespect®), which is now commercialized in the US, Europe, Canada, and other territories. Valneva will use the expertise the company has gained with the development of this Japanese Encephalitis vaccine to evaluate the technical feasibility of developing a vaccine and delivering a lead candidate within two years.
(FDA, Health Canada), European (EMA) and other regulatory agencies and is today commercialized in the US, Europe, Canada, and other territories under the tradenames Ixiaro®/ Jespect®.
